These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 7495996

  • 1. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).
    Saito H, Sato K, Tomioka H, Dekio S.
    Tuber Lung Dis; 1995 Oct; 76(5):377-80. PubMed ID: 7495996
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [In vitro antimycobacterial activity of a new quinolone, T-3761].
    Tomioka H, Sato K, Saito H.
    Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
    Tomioka H, Sato K, Saito H.
    Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
    Kawahara S, Tada A, Nagare H.
    Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S, Pellegrin JL, Leblanc F, Fourche J, Maugein J.
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M.
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
    Saito H, Tomioka H, Sato K, Dekio S.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimycobacterial activities of novel levofloxacin analogues.
    Kawakami K, Namba K, Tanaka M, Matsuhashi N, Sato K, Takemura M.
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2126-9. PubMed ID: 10898685
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K, Tomioka H, Akaki T, Kawahara S.
    Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
    [Abstract] [Full Text] [Related]

  • 18. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
    Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Barbara-Burnham L, Young LS.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):546-51. PubMed ID: 8851568
    [Abstract] [Full Text] [Related]

  • 19. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K, Ogasawara K, Akaki T, Tomioka H.
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [Abstract] [Full Text] [Related]

  • 20. [In vitro antimicrobial activity of a new quinolone, levofloxacin, against atypical mycobacteria].
    Oya S, Takemoto A, Hosaka K, Kudou Y, Arakawa M.
    Kekkaku; 1995 Nov; 70(11):615-9. PubMed ID: 8656585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.